Leukaemia Trial, Recruiting NCT06446661 Sponsor: University of Chicago Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT06446661
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 15 years of age or older at the time of joining the trial
  • People who have been diagnosed with ALL (acute lymphoblastic leukemia) or T-cell lymphoblastic lymphoma (a type of blood cancer)
  • People who are currently being treated with a treatment plan that includes a maintenance phase using two medicines called mercaptopurine and methotrexate (for example, a plan called CALGB 10403) — enrollment happens before or at the start of the maintenance phase, though people in the early pilot phase may have already started maintenance, as long as their maintenance treatment is not scheduled to end before the 28-day pilot period is over
  • People whose preferred language for medical communication is something other than English are still eligible, as text messages used in the trial can be sent in the patient's preferred language

Who may not be able to join:

  • People where neither the patient nor their caregiver has a mobile phone that can receive text messages
  • People who do not wish to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Austin Wesevich, University of Chicago

Phone: 1-855-702-8222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
19 May 2026
Est. completion
15 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To compare adherence to oral chemotherapy between study groups for first treatment cycle (Efficacy Phase); Feasibility of text message interventions to improve adherence to oral chemotherapy (Pilot Phase)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov